BR9915420A - Composto, composição farmacêutica, métodos de tratar um distúrbio mediado por tnf e por p38 cinase, inflamação e artrite e processo de preparar pirazóis - Google Patents

Composto, composição farmacêutica, métodos de tratar um distúrbio mediado por tnf e por p38 cinase, inflamação e artrite e processo de preparar pirazóis

Info

Publication number
BR9915420A
BR9915420A BR9915420-0A BR9915420A BR9915420A BR 9915420 A BR9915420 A BR 9915420A BR 9915420 A BR9915420 A BR 9915420A BR 9915420 A BR9915420 A BR 9915420A
Authority
BR
Brazil
Prior art keywords
kinase
tnf
arthritis
inflammation
treating
Prior art date
Application number
BR9915420-0A
Other languages
English (en)
Inventor
Ashok Anantanarayan
Michael Clare
Paul W Collins
Joyce Z Crich
Rajesh Devraj
Daniel L Flynn
Lifeng Geng
Matthew J Graneto
Cathleen D Hanau
Gunnar J Hanson
Susan J Hartmann
Michael Hepperle
He Huang
Ish K Khanna
Francis J Koszyk
Shuyuan Liao
Suzanne Metz
Richard A Partis
Thao D Perry
Shashidhar N Rao
Shaun Raj Selness
Michael S South
Michael A Stealey
John Jeffrey Talley
Michael L Vasquez
Richard M Weier
Xiangdong Xu
Yi Yu
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of BR9915420A publication Critical patent/BR9915420A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, MéTODOS DE TRATAR UM DISTúRBIO MEDIADO POR TNF E POR P38 CINASE, INFLAMAçãO E ARTRITE E PROCESSO DE PREPARAR PIRAZóIS". Uma classe de derivados de pirazóis é descrita para o uso no tratamento de distúrbios mediados pela p38 cinase. Os compostos de interesse particular são definidos pela Fórmula (1A), em que R^ 1^, R^ 2^, R^ 3^ e R^ 4^ são como descritos no relatório descritivo.
BR9915420-0A 1998-11-20 1999-11-17 Composto, composição farmacêutica, métodos de tratar um distúrbio mediado por tnf e por p38 cinase, inflamação e artrite e processo de preparar pirazóis BR9915420A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/196,623 US6514977B1 (en) 1997-05-22 1998-11-20 Substituted pyrazoles as p38 kinase inhibitors
PCT/US1999/026007 WO2000031063A1 (en) 1998-11-20 1999-11-17 SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS

Publications (1)

Publication Number Publication Date
BR9915420A true BR9915420A (pt) 2002-01-22

Family

ID=22726159

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9915420-0A BR9915420A (pt) 1998-11-20 1999-11-17 Composto, composição farmacêutica, métodos de tratar um distúrbio mediado por tnf e por p38 cinase, inflamação e artrite e processo de preparar pirazóis

Country Status (35)

Country Link
US (5) US6514977B1 (pt)
EP (2) EP1500657B1 (pt)
JP (1) JP2002530397A (pt)
KR (1) KR20030002291A (pt)
CN (1) CN1342157A (pt)
AP (1) AP2001002172A0 (pt)
AR (1) AR035836A1 (pt)
AT (2) ATE373649T1 (pt)
AU (1) AU774262B2 (pt)
BG (1) BG105620A (pt)
BR (1) BR9915420A (pt)
CA (1) CA2351725A1 (pt)
CZ (1) CZ20011714A3 (pt)
DE (2) DE69920966T2 (pt)
DK (2) DK1500657T3 (pt)
EA (1) EA005205B1 (pt)
EE (1) EE200100268A (pt)
ES (2) ES2289411T3 (pt)
GE (1) GEP20053421B (pt)
HK (1) HK1040705B (pt)
HR (1) HRP20010363A2 (pt)
HU (1) HUP0200130A2 (pt)
ID (1) ID29993A (pt)
IL (1) IL143120A0 (pt)
IS (1) IS5938A (pt)
NO (1) NO20012456L (pt)
NZ (1) NZ512344A (pt)
OA (1) OA11914A (pt)
PL (1) PL353853A1 (pt)
PT (2) PT1144403E (pt)
SK (1) SK6862001A3 (pt)
TR (1) TR200102001T2 (pt)
WO (1) WO2000031063A1 (pt)
YU (1) YU35601A (pt)
ZA (1) ZA200103882B (pt)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US7517880B2 (en) * 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
EP1112070B1 (en) * 1998-08-20 2004-05-12 Smithkline Beecham Corporation Novel substituted triazole compounds
CN1326848C (zh) * 1998-12-25 2007-07-18 帝国脏器制药株式会社 氨基吡唑衍生物
CA2359244C (en) 1999-01-13 2013-10-08 Bayer Corporation .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1022027A1 (en) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Tumor necrosis factor antagonists and their use in endometriosis
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
PT1169038E (pt) 1999-04-15 2012-10-26 Bristol Myers Squibb Co Inibidores cíclicos da proteína tirosina cinase
JP4627944B2 (ja) 1999-06-03 2011-02-09 あすか製薬株式会社 置換ピラゾール化合物
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
CN1222520C (zh) * 1999-08-12 2005-10-12 沃泰克斯药物股份有限公司 c－JUN N－末端激酶(JNK)和其它蛋白激酶的抑制剂
US6759410B1 (en) * 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
NZ514583A (en) * 2000-02-05 2004-05-28 Vertex Pharma Pyrazole compositions useful as inhibitors of ERK
DE10029077A1 (de) * 2000-06-13 2001-12-20 Bayer Ag Thiazolylsubstituierte Heterocyclen
DE10037310A1 (de) 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
EP1313729B1 (en) 2000-08-17 2007-03-21 Lumera Corporation Design and synthesis of thiophene derived nlo materials for electro-optic applications
AU2002228783A1 (en) * 2000-12-05 2002-06-18 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
EP1361225B1 (en) 2001-01-22 2007-11-07 Sankyo Company, Limited Compounds substituted with bicyclic amino groups
WO2002062792A1 (fr) * 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Inhibiteur de jnk
EP1382603B1 (en) 2001-04-26 2008-07-23 Eisai R&D Management Co., Ltd. Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof
US6856992B2 (en) * 2001-05-15 2005-02-15 Metatomix, Inc. Methods and apparatus for real-time business visibility using persistent schema-less data storage
CA2446864C (en) 2001-05-16 2011-02-15 Vertex Pharmaceuticals Incorporated Inhibitors of src and other protein kinases
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
EP1419770A4 (en) * 2001-08-24 2005-08-03 Shionogi & Co AGENT ACC L RATION OF THE EXPRESSION OF APO AI
US6897318B2 (en) * 2001-09-25 2005-05-24 Pharmacia Corporation Process for making substituted pyrazoles
US7057049B2 (en) * 2001-09-25 2006-06-06 Pharmacia Corporation Process for making substituted pyrazoles
WO2003026662A1 (en) * 2001-09-25 2003-04-03 Pharmacia Corporation Solid-state forms of n-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl)pyrazole
DE10152005A1 (de) * 2001-10-22 2003-04-30 Bayer Cropscience Ag Pyrazolylsubstituierte Heterocyclen
US20030087442A1 (en) * 2001-11-08 2003-05-08 Ioana Popa-Burke Sample preparation system and associated apparatuses and method
GB0129476D0 (en) * 2001-12-10 2002-01-30 Syngenta Participations Ag Organic compounds
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
OA12771A (en) * 2002-02-14 2006-07-04 Pharmacia Corp Substituted pyridinones as modulators of P38 map kinase.
ES2281633T3 (es) * 2002-02-19 2007-10-01 Pfizer Italia S.R.L. Derivados triciclicos de pirazol, procedimiento para su preparacion y su uso como agentes antitumorales.
US20030187632A1 (en) * 2002-04-02 2003-10-02 Menich Barry J. Multimedia conferencing system
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
EP1513817A1 (en) * 2002-05-24 2005-03-16 Takeda Pharmaceutical Company Limited 1, 2-azole derivatives with hypoglycemic and hypolipidemic activity
AU2003237446A1 (en) * 2002-06-05 2003-12-22 Pharmacia Corporation Pyrazole-derivatives as p38 kinase inhibitors
GB0215844D0 (en) * 2002-07-09 2002-08-14 Novartis Ag Organic compounds
DE60310730T2 (de) 2002-07-09 2007-05-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege
EP1541571A4 (en) * 2002-07-19 2008-12-03 Sankyo Co BICYCLIC, UNSATURATED TERTIARY AMINE COMPOUND
GB0217786D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
PA8578101A1 (es) 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
TW200413351A (en) 2002-08-21 2004-08-01 Astrazeneca Ab Chemical compounds
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
PL379544A1 (pl) * 2002-09-09 2006-10-02 Amgen Inc. 1,4,5-podstawione pochodne 1,2-dihydro-pirazol-3-onu i 3-alkoksy 1H-pirazolu jako środki obniżające poziom TNF-alfa oraz interleukin do leczenia stanów zapalnych
JP2006502236A (ja) 2002-09-18 2006-01-19 ファイザー・プロダクツ・インク 形質転換成長因子（ｔｇｆ）阻害剤としてのトリアゾール誘導体
BR0314383A (pt) 2002-09-18 2005-07-19 Pfizer Prod Inc Compostos de oxazol e tiazol como inibidores do fator de crescimento transformante(tgf)
EA200500378A1 (ru) 2002-09-18 2005-08-25 Пфайзер Продактс Инк. Новые соединения имидазола в качестве ингибиторов трансформирующего фактора роста (tgf)
WO2004026306A2 (en) 2002-09-18 2004-04-01 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
PL375973A1 (en) 2002-09-18 2005-12-12 Pfizer Products Inc. Novel isothiazole and isoxazole compounds as transforming growth factor (tgf) inhibitors
CN100519552C (zh) 2002-09-25 2009-07-29 宇部兴产株式会社 吡唑化合物
KR100462989B1 (ko) * 2002-10-07 2004-12-23 엘지전자 주식회사 음성 프롬프트 보드의 음성 토큰 관리 방법
US20050288299A1 (en) * 2002-10-09 2005-12-29 Mavunkel Babu J Azaindole derivatives as inhibitors of p38 kinase
GB0229618D0 (en) 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
AU2003301226A1 (en) * 2002-12-20 2004-07-22 Pharmacia Corp Acyclic pyrazole compounds for the inhibition of mitogen activated protein kinase-activated protein kinase-2
CL2004000366A1 (es) * 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
EP1606019A1 (en) * 2003-03-07 2005-12-21 The University Court of The University of Aberdeen Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders
FR2854159B1 (fr) * 2003-04-25 2008-01-11 Aventis Pharma Sa Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr
PT1626714E (pt) 2003-05-20 2007-08-24 Bayer Pharmaceuticals Corp Diarilureias para doenças mediadas por pdgfr
ES2297490T3 (es) 2003-07-23 2008-05-01 Bayer Pharmaceuticals Corporation Omega-carboxiarildifenilurea fluoro sustituida para el tratamiento y prevencion de enfermadades y afecciones.
CL2004002050A1 (es) * 2003-08-13 2005-06-03 Pharmacia Corp Sa Organizada B Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
US7223759B2 (en) * 2003-09-15 2007-05-29 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds
BRPI0417543A (pt) * 2003-12-12 2007-03-27 Wyeth Corp quinolinas úteis no tratamento de doença cardiovascular
WO2005061485A1 (en) * 2003-12-18 2005-07-07 Pharmacia Corporation Process for making substituted pyrazoles
EP2228369A1 (en) 2003-12-23 2010-09-15 Astex Therapeutics Ltd. Pyrazole derivatives as protein kinase modulators
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
CN1968922A (zh) * 2004-06-18 2007-05-23 米伦纽姆医药公司 因子xa抑制剂
ES2565848T3 (es) * 2004-07-07 2016-04-07 Biocon Limited Síntesis de compuestos inmunorreguladores unidos por grupos azoicos
WO2006020365A2 (en) * 2004-07-26 2006-02-23 The Regents Of The University Of California Method for prevention or treatment of inflamatory disease
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
GEP20104973B (en) * 2004-08-12 2010-04-26 Pfizer Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
US8143425B2 (en) * 2004-10-12 2012-03-27 Bristol-Myers Squibb Company Heterocyclic aromatic compounds useful as growth hormone secretagogues
TW200633990A (en) * 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
JP5123671B2 (ja) * 2005-02-17 2013-01-23 シンタ ファーマシューティカルズ コーポレーション 増殖性疾患の治療のための化合物
WO2006116355A1 (en) * 2005-04-22 2006-11-02 Kalypsys, Inc. Ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
WO2006131807A1 (en) * 2005-06-06 2006-12-14 Pfizer Products Inc. Preparation of 3-amino-4,5-disubstituted-pyrazole derivatives
JP2008546751A (ja) 2005-06-22 2008-12-25 アステックス・セラピューティクス・リミテッド 医薬組成物
JP5345842B2 (ja) 2005-06-23 2013-11-20 アステックス・セラピューティクス・リミテッド プロテインキナーゼモジュレーターとしてのピラゾール誘導体を含む医薬組み合わせ
EP1935881B1 (en) * 2005-09-30 2012-04-04 Msd K.K. Aryl-substituted nitrogen-containing heterocyclic compound
EP1829873A1 (en) * 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Pyrrazole derivatives as sigma receptors antagonists
WO2007131179A1 (en) * 2006-05-05 2007-11-15 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
US8314136B1 (en) 2006-05-23 2012-11-20 MedDEV, Inc. Method for treatment of alzheimer's disease and autism spectrum disorders
US7666893B2 (en) * 2006-05-23 2010-02-23 Meddev Inc. Method for treatment of neurodegenerative disorders
EP2036905B1 (en) 2006-06-28 2012-12-12 ASKA Pharmaceutical Co., Ltd. Pyridylisoxazole derivative
EP2044957A4 (en) * 2006-06-28 2011-01-05 Aska Pharm Co Ltd TREATMENT AGENT FOR INFLAMMATORY BOWEL DISEASE
WO2008013622A2 (en) * 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
US9090604B2 (en) 2006-07-27 2015-07-28 E I Du Pont De Nemours And Company Fungicidal azocyclic amides
AU2008205093A1 (en) * 2007-01-05 2008-07-17 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
GB0702862D0 (en) * 2007-02-14 2007-03-28 Univ Aberdeen Therapeutic compounds
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
US20080248548A1 (en) * 2007-04-09 2008-10-09 Flynn Daniel L Modulation of protein functionalities
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
JP5603770B2 (ja) * 2007-05-31 2014-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２受容体拮抗薬およびその使用
CA2695114A1 (en) * 2007-08-01 2009-02-05 Pfizer Inc. Pyrazole compounds and their use as raf inhibitors
CL2009000904A1 (es) 2008-04-21 2010-04-30 Shionogi & Co Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
EA019722B1 (ru) 2008-07-24 2014-05-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ
CA2735204C (en) * 2008-08-25 2017-06-20 Boehringer Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use
EA020548B1 (ru) 2008-12-19 2014-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Циклические пиримидин-4-карбоксамиды в качестве антагонистов рецептора ccr2, предназначенные для лечения воспаления, астмы и хозл
WO2010101246A1 (ja) * 2009-03-05 2010-09-10 塩野義製薬株式会社 Ｎｐｙ ｙ５受容体拮抗作用を有するピペリジンおよびピロリジン誘導体
EP2430013B1 (en) * 2009-05-13 2014-10-15 Amgen Inc. Heteroaryl compounds as pikk inhibitors
PL2432767T3 (pl) * 2009-05-19 2013-11-29 Dow Agrosciences Llc Związki i sposoby zwalczania grzybów
KR101111247B1 (ko) 2009-07-17 2012-06-12 한국과학기술연구원 Ｒｏｓ 카이네이즈 저해활성을 갖는 피라졸 화합물
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
EP2308866A1 (de) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
AR078887A1 (es) 2009-11-06 2011-12-07 Boehringer Ingelheim Int Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina y composiciones farmaceuticas que los contienen.
MX2012006964A (es) 2009-12-17 2012-07-17 Boehringer Ingelheim Int Nuevos antagonistas del receptor ccr2 y usos de los mismos.
US8742120B2 (en) 2009-12-17 2014-06-03 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
JP5796872B2 (ja) * 2009-12-17 2015-10-21 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 第Ｘａ因子阻害剤の結晶性塩
CN102762551A (zh) 2009-12-21 2012-10-31 拜尔农作物科学股份公司 噻吩基吡(嘧)啶基吡唑及其用于防治植物致病菌的用途
EP2528909B1 (en) 2010-01-27 2016-06-22 Nerviano Medical Sciences S.r.l. Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors
AR081810A1 (es) 2010-04-07 2012-10-24 Bayer Cropscience Ag Piridinilpirazoles biciclicos
JP2013526507A (ja) 2010-05-12 2013-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２受容体アンタゴニスト、その製造方法及び薬物としてのその使用
WO2011141477A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8841313B2 (en) 2010-05-17 2014-09-23 Boehringer Ingelheim International Gmbh CCR2 antagonists and uses thereof
EP2576542B1 (en) 2010-05-25 2015-04-22 Boehringer Ingelheim International GmbH Cyclic amide derivatives of pyridazine-3-carboxylic acids and their use in the treatment of pulmonary, pain, immune related and cardiovascular diseases
US8962656B2 (en) 2010-06-01 2015-02-24 Boehringer Ingelheim International Gmbh CCR2 antagonists
EP2402339A1 (en) * 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
EP2601185B1 (en) 2010-08-03 2015-10-07 Nerviano Medical Sciences S.r.l. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents
TWI537258B (zh) 2010-11-05 2016-06-11 百靈佳殷格翰國際股份有限公司 六氫茚并吡啶及八氫苯并喹啉之芳基－及雜環芳基羰基衍生物
WO2012078674A1 (en) * 2010-12-06 2012-06-14 Confluence Life Sciences, Inc. Substituted indole/indazole-pyrimidinyl compounds
PT2668183T (pt) * 2011-01-28 2018-02-05 4Sc Discovery Gmbh Inibição de il-7 e de ifn gama para o tratamento de inflamação autoimune
AR086992A1 (es) 2011-06-20 2014-02-05 Bayer Ip Gmbh Tienilpiri(mi)dinilpirazoles
JP5786258B2 (ja) 2011-07-15 2015-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規かつ選択的なｃｃｒ２拮抗薬
EP2763993B1 (en) 2011-10-06 2017-04-19 Bayer Intellectual Property GmbH Heterocyclylpyri(mi)dinylpyrazole
MX355016B (es) 2011-10-06 2018-04-02 Bayer Ip Gmbh Heterociclilpiri(mi)dinilpirazoles como fungicidas.
CN108542906A (zh) 2011-11-11 2018-09-18 诺华股份有限公司 治疗增生性疾病的方法
SI2782557T1 (sl) 2011-11-23 2019-02-28 Array Biopharma, Inc., Farmacevtske formulacije
US20150044178A1 (en) 2011-12-28 2015-02-12 Kyoto Prefectural Public University Corporation Normalization of culture of corneal endothelial cells
BR102012024778A2 (pt) * 2012-09-28 2014-08-19 Cristalia Prod Quimicos Farm Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
KR102283996B1 (ko) 2013-03-15 2021-07-29 더 스크립스 리서치 인스티튜트 연골형성의 유도를 위한 화합물 및 방법
WO2014199164A1 (en) * 2013-06-12 2014-12-18 Ampla Pharmaceuticals, Inc. Diaryl substituted heteroaromatic compounds
EP3069732B1 (en) 2013-11-14 2023-07-12 The Doshisha Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage
KR102405136B1 (ko) 2014-05-16 2022-06-07 아트리바 테라퓨틱스 게엠베하 인플루엔자 바이러스 및 에스. 아우레우스 공감염에 대한 신규한 항-감염 전략
CN107205970A (zh) 2014-11-05 2017-09-26 弗莱塞斯生物科学公司 免疫调节剂
ES2791340T3 (es) * 2015-05-27 2020-11-03 Kyorin Seiyaku Kk Derivado de urea o sal farmacológicamente aceptable del mismo
JP6917910B2 (ja) 2015-07-02 2021-08-11 セントレクシオン セラピューティクス コーポレイション （４−（（３ｒ，４ｒ）−３−メトキシテトラヒドロ−ピラン−４−イルアミノ）ピペリジン−１−イル）（５−メチル−６−（（（２ｒ，６ｓ）−６−（ｐ−トリル）テトラヒドロ−２ｈ−ピラン−２−イル）メチルアミノ）ピリミジン−４イル）メタノンクエン酸塩
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
CN107400088B (zh) * 2017-08-16 2020-04-28 山东大学 1,3-二取代吡唑类衍生物及其制备方法与应用
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
CN112457255B (zh) * 2017-11-08 2022-08-19 北京嘉林药业股份有限公司 化合物及其治疗癌症的用途
CA3094324A1 (en) 2018-03-26 2019-10-03 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
CN112204017B (zh) * 2018-04-27 2024-08-20 国立大学法人大阪大学 苯并异噁唑化合物
CN110437220B (zh) * 2018-07-13 2022-12-27 暨南大学 三氮唑类化合物及其应用
JP2023509452A (ja) 2020-01-03 2023-03-08 バーグ エルエルシー がんを処置するためのｕｂｅ２ｋモジュレータとしての多環式アミド
US20210300873A1 (en) 2020-03-20 2021-09-30 Clear Creek Bio, Inc. Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof
EP3978487A1 (en) * 2020-09-30 2022-04-06 Origo Biopharma, S.L. 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5
IL305573A (en) 2021-03-15 2023-10-01 Saul Yedgar Hyaluronic acid conjugated with dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment or suppression of inflammatory diseases
WO2023280911A1 (en) 2021-07-06 2023-01-12 Westfälische Wilhelms-Universität Münster P38-inhibitors for the treatment of coronavirus infections and/or covid-19 cytokine storm
WO2023004280A1 (en) * 2021-07-19 2023-01-26 The Board Of Trustees Of The Leland Stanford Junior University Selective pyrazole lrrk2 inhibitors and methods for use thereof
CN114262308B (zh) * 2021-12-20 2024-01-09 华东师范大学 一类2-亚甲基-2,3-二氢噻唑类化合物及其合成方法和应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE295374C (pt)
DE1261124B (de) 1961-09-22 1968-02-15 Hoechst Ag Verfahren zur Herstellung von Pyrazolen
GB1245283A (en) 1968-10-04 1971-09-08 Labaz Pyrazole derivatives
US3984431A (en) 1972-03-15 1976-10-05 Claude Gueremy Derivatives of pyrazole-5-acetic acid
FR2509729A1 (fr) 1981-07-15 1983-01-21 Pharmindustrie Nouveau procede de preparation de derives du diphenyl-3,4 methyl-5 pyrazole
DE3300795A1 (de) 1983-01-12 1984-07-12 Bayer Ag, 5090 Leverkusen Substituierte 4-imidazolyl-pyrazole, verfahren zu ihrer herstellung sowie diese enthaltende arzneimittel
US5051518A (en) 1987-05-29 1991-09-24 Ortho Pharmaceutical Corporation Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-N-hydroxypropanamides
PH27357A (en) 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
JP2753659B2 (ja) 1990-09-03 1998-05-20 株式会社大塚製薬工場 ピラゾール誘導体
DD295374A5 (de) * 1990-09-13 1991-10-31 Sterling Drug Inc.,Us Neue n-[(alkylamino)-alkyl]-4,-5-diaryl-1h-pyrazol-1-acetamide und verfahren zur herstellung
JPH04145081A (ja) 1990-10-06 1992-05-19 Kumiai Chem Ind Co Ltd ピラゾールカルボン酸誘導体及び除草剤
AU1988692A (en) 1991-04-24 1992-12-21 E.I. Du Pont De Nemours And Company Fungicidal pyrazoles, pyrazolines and tetrahydropyridazines
US5356897A (en) 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
GB9204958D0 (en) 1992-03-06 1992-04-22 Fujisawa Pharmaceutical Co Thiazole derivatives
GB9303993D0 (en) 1993-02-26 1993-04-14 Fujisawa Pharmaceutical Co New heterocyclic derivatives
US5593992A (en) 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
DE4328228A1 (de) 1993-08-23 1995-03-02 Basf Ag Verfahren zur Herstellung von Pyrazol und dessen Derivaten
TW327171B (en) 1994-02-18 1998-02-21 Boehringer Ingelheim Pharma 2-heteroaryl-5 for prevention or treatment of HIV infection
US5559137A (en) 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US5486534A (en) 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
JPH0899975A (ja) 1994-08-05 1996-04-16 Nippon Bayeragrochem Kk ５員複素環置換テトラゾリノン誘導体および除草剤
JP3734180B2 (ja) 1994-12-28 2006-01-11 エーザイ株式会社 新規ピラゾール誘導体
KR19980701374A (ko) 1995-01-12 1998-05-15 스티븐 베네티아너 신규 화합물(Novel Compounds)
IL118544A (en) 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
US5739143A (en) 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
JPH11508267A (ja) 1995-06-26 1999-07-21 藤沢薬品工業株式会社 ピラゾール化合物および医薬組成物
US5756529A (en) 1995-09-29 1998-05-26 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
ZA9610687B (en) 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
AP9700912A0 (en) 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
ZA97175B (en) 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
JP2001508395A (ja) 1996-01-11 2001-06-26 スミスクライン・ビーチャム・コーポレイション 新規シクロアルキル置換イミダゾール
WO1997032583A1 (en) 1996-03-08 1997-09-12 Smithkline Beecham Corporation Use of csaidtm compounds as inhibitors of angiogenesis
US6235760B1 (en) 1996-03-25 2001-05-22 Smithkline Beecham Corporation Treatment for CNS injuries
US6096739A (en) 1996-03-25 2000-08-01 Smithkline Beecham Corporation Treatment for CNS injuries
JP3418624B2 (ja) 1996-06-10 2003-06-23 メルク エンド カンパニー インコーポレーテッド サイトカイン阻害活性を有する置換イミダゾール類
WO1998007425A1 (en) 1996-08-21 1998-02-26 Smithkline Beecham Corporation Imidazole compounds, compositions and use
AU5147598A (en) 1996-10-17 1998-05-11 Smithkline Beecham Corporation Methods for reversibly inhibiting myelopoiesis in mammalian tissue
GB9625045D0 (en) 1996-11-30 1997-01-22 Pfizer Ltd Parasiticidal compounds
ID18983A (id) 1996-12-04 1998-05-28 Lilly Co Eli Pirazola sebagai inhibitor sekresi fosfolipase a2 non-pankreas pada manusia
ZA9711092B (en) 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
AU7726898A (en) * 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
EP0983260A2 (en) 1997-05-22 2000-03-08 G.D. Searle & Co. 3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
GEP20033053B (en) * 1997-05-22 2003-08-25 Searle & Co Substituted Pyrazoles as P38 Kinase Inhibitors, Methods for their Production, Pharmaceutical Compositions Containing Them and Methods for Treatment
US6610695B1 (en) 1997-06-19 2003-08-26 Smithkline Beecham Corporation Aryloxy substituted pyrimidine imidazole compounds
AU8381098A (en) 1997-07-02 1999-01-25 Smithkline Beecham Corporation Novel cycloalkyl substituted imidazoles
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
AR016294A1 (es) 1997-07-02 2001-07-04 Smithkline Beecham Corp Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion
EP1041989A4 (en) 1997-10-08 2002-11-20 Smithkline Beecham Corp NEW SUBSTITUTED CYCLOALCENYL COMPOUNDS
AR017219A1 (es) 1997-12-19 2001-08-22 Smithkline Beecham Corp Derivados de imidazol 1,4,5 sustituidos, composiciones que los comprenden, procedimiento para la preparacion de dichos derivados, uso de los derivados parala manufactura de un medicamento
NZ508790A (en) 1998-05-22 2003-10-31 Scios Inc Heterocyclic compounds and methods to treat cardiac failure and other disorders

Also Published As

Publication number Publication date
US6514977B1 (en) 2003-02-04
HK1040705B (zh) 2005-03-04
DK1500657T3 (da) 2008-01-02
CA2351725A1 (en) 2000-06-02
HK1040705A1 (en) 2002-06-21
EP1500657B1 (en) 2007-09-19
NZ512344A (en) 2003-11-28
US7153959B2 (en) 2006-12-26
JP2002530397A (ja) 2002-09-17
US20040176433A1 (en) 2004-09-09
US6525059B1 (en) 2003-02-25
CN1342157A (zh) 2002-03-27
WO2000031063A1 (en) 2000-06-02
DE69937163T2 (de) 2008-05-21
KR20030002291A (ko) 2003-01-08
ES2289411T3 (es) 2008-02-01
AU774262B2 (en) 2004-06-24
DE69920966D1 (de) 2004-11-11
AP2001002172A0 (en) 2001-06-30
EP1500657A1 (en) 2005-01-26
IS5938A (is) 2001-05-09
GEP20053421B (en) 2005-01-25
DK1144403T3 (da) 2004-12-20
DE69920966T2 (de) 2006-03-09
EA005205B1 (ru) 2004-12-30
ATE373649T1 (de) 2007-10-15
US6423713B1 (en) 2002-07-23
EP1144403B1 (en) 2004-10-06
IL143120A0 (en) 2002-04-21
CZ20011714A3 (cs) 2001-12-12
NO20012456D0 (no) 2001-05-18
ES2229809T3 (es) 2005-04-16
DE69937163D1 (de) 2007-10-31
PT1500657E (pt) 2007-12-05
ZA200103882B (en) 2002-10-14
US6617324B1 (en) 2003-09-09
AU2145400A (en) 2000-06-13
EA200100554A1 (ru) 2001-12-24
OA11914A (en) 2006-04-11
ID29993A (id) 2001-10-25
ATE278685T1 (de) 2004-10-15
HRP20010363A2 (en) 2005-02-28
BG105620A (bg) 2002-01-31
EE200100268A (et) 2002-12-16
HUP0200130A2 (en) 2002-06-29
PL353853A1 (en) 2003-12-01
PT1144403E (pt) 2005-01-31
YU35601A (sh) 2005-07-19
TR200102001T2 (tr) 2001-12-21
SK6862001A3 (en) 2002-06-04
NO20012456L (no) 2001-07-19
AR035836A1 (es) 2004-07-21
EP1144403A1 (en) 2001-10-17

Similar Documents

Publication Publication Date Title
BR9915420A (pt) Composto, composição farmacêutica, métodos de tratar um distúrbio mediado por tnf e por p38 cinase, inflamação e artrite e processo de preparar pirazóis
BR9809147A (pt) Composto pirazol substituìdo, composição farmacêutica, processos para tratar um distúrbio mediado por tnf, um distúrbio mediado por quinase p38, inflamação e artrite, e, para preparar pirazóis
BR9808953A (pt) Composto, processo para tratar um distúrbio mediado pela ciclooxigenase-2 em um paciente, e, composição farmacêutica
BR9916282A (pt) Composto, uso de um um composto e método de tratamento
BR9914696A (pt) Composto, processo para tratamento de distúrbio mediado por ciclo-oxigenase-2 em um indivìduo, e, composição farmacêutica
BR0317717A (pt) Composto, composição farmacêutica, uso de um composto, método para tratar um humano sofrendo de uma doença, e, processo para a preparação de um composto
BR0307351A (pt) Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto
BR0312464A (pt) Inibidores de tirosina quinases
BR9507917A (pt) Reagente para preparar um agente radiofarmacêutico agente formador de imagem processo para preparar o mesmo kit para preparar uma preparação farmacêutica uso do reagente agente radioterapêutico composição e agente radiofarmacêutico
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
BRPI0215312B8 (pt) composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
BR0206435A (pt) Composto, composição farmacêutica, métodos de tratar a angiogênese em um paciente, de tratar distúrbios relacionados com kdr e proliferativos em um mamìfero, uso de um composto, e, processo para preparar compostos
DK0675886T3 (da) Aminomethylensubstituerede ikke-aromatiske heterocykler og deres anvendelse som substance P-antagonister
BR9303993A (pt) Composto, processo para preparar o mesmo e composição farmacêutica
BRPI0614168A2 (pt) Composto ou um sal, hidrato, solvato, isoforma, tautômero, isômero óptico farmaceuticamente aceitável ou uma combinação dos mesmos, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psquiátricos, uso de um composto, e, processo para a preparação de um composto
BR9810592A (pt) Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto
BR9714082A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto.
AR002267A1 (es) Compuestos de imidazol utiles para el tratamiento de patologias mediadas por citoquinas; composicion farmaceutica que los contiene; proceso para preparar dichos compuestos; uso del mismo para preparar dichas composiciones; compuestos intermediarios y procesos para su preparacion.
BR9911488A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou de profilaxia de doenças inflamatórias, e para a preparação de um composto
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
BRPI0416004A (pt) composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método para o tratamento de doenças mediadas por glk, uso de um composto ou um sal, solvato ou pró-droga do mesmo, métodos para o tratamento combinado de obesidade e diabetes e para o tratamento de obesidade, e, processo para a preparação de um composto ou um sal, pró-droga ou solvato do mesmo
BRPI0411508A (pt) composto, formulação farmacêutica, uso de um composto, método para tratar doenças, e, processo para preparar um composto
BR0108600A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, métodos para tratamento de uma doença mediada por quimiocina e para tratamento de uma doença inflamatória
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
BR9407257A (pt) Composto do tipo bis-naftalimida composição farmacêutica processo para tratamento de um tumor em mamifero uso do composto do tipo bis-naftalimida e processo para a preparação compostos do tipo bis-naftalimida

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM ARTIGOS 8O, 11, 13, 24 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.